Compare Becton Dickinson and Co (BDX) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Berkshire Hathaway Inc Class B — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Berkshire Hathaway Inc Class B trades at $491.01. The key difference: Becton Dickinson and Co pays a 2.79% dividend while Berkshire Hathaway Inc Class B pays none, and Berkshire Hathaway Inc Class B is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| BDX | BRK.B | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Financials |
52-Week High | $185.39 | $513.70 |
52-Week Low | $135.49 | $459.10 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
BRK.B trades at $496.79, up 0.63% today, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The stock is supported by strong analyst consensus with 57% buy ratings and no sell recommendations. Recent earnings reports highlight Berkshire Hathaway's diversified portfolio strength and consistent cash flow generation.
The outlook remains positive given institutional confidence and technical support near $494, though investors face risks from macroeconomic sensitivity and regulatory scrutiny. Upside potential exists if the company maintains its earnings momentum and capital allocation strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →
